AIMC Topic: Treatment Outcome

Clear Filters Showing 71 to 80 of 3321 articles

Retrospective study of onychomycosis patients treated with ciclopirox 8% HPCH and oral antifungals applying artificial intelligence to electronic health records.

Scientific reports
We conducted a multicenter retrospective analysis of 408 patients diagnosed with onychomycosis who attended three tertiary care Spanish hospitals. The study was conducted to assess the clinical characteristics and outcomes of onychomycosis patients u...

Artificial intelligence in hepatopancreatobiliary surgery for clinical outcome prediction: current perspective and future direction.

Journal of robotic surgery
The expanding and evolving role of artificial intelligence (AI) in surgery has been enhanced by the adoption of robotic-assisted surgery (RAS), which provides a platform to facilitate the integration and utilisation of AI technologies. One area where...

Ultrasound-based machine learning models for predicting response to neoadjuvant chemotherapy in breast cancer: A meta-analysis.

Clinical imaging
BACKGROUND AND AIMS: Breast cancer remains the most common cancer among women globally, with neoadjuvant chemotherapy (NAC) serving as a critical pre-surgical intervention. Ultrasound-based radiomics and machine learning (ML) models offer potential f...

Optimizing treatment for depression in primary care using psychotherapy versus antidepressant medication in a low-resource setting: protocol for the OptimizeD randomized controlled trial.

BMC psychiatry
BACKGROUND: Psychotherapy and antidepressant medications are first-line treatments for depression, and they both have significant treatment effects on average. However, treatment response varies widely across patients, and neither approach is univers...

Analysis of liquid biopsy by Raman spectroscopy to facilitate prediction of response to immunotherapy in non-small-cell lung cancer (NSCLC) patients.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
Immunotherapy has revolutionized lung cancer treatment, yet predicting patient response remains a challenge. This study used Raman spectroscopy to differentiate between non-small-cell lung cancer patients with short-lasting and long-lasting responses...

Machine learning-based high-benefit approach versus traditional high-risk approach in statin therapy: the Shizuoka Kokuho database study.

Scientific reports
Statins are widely prescribed for the primary prevention of cardiovascular diseases, yet individual responses vary, necessitating personalized treatment strategies. Conventional approaches prioritize treating high-risk patients, but advancements in m...

Evidence Based Gait Analysis Interpretation Tools (EB-GAIT) treatment recommendation and outcome prediction models to support decision-making based on clinical gait analysis data.

PloS one
Clinical gait analysis (CGA) has historically relied on clinician experience and judgment, leading to modest, stagnant, and unpredictable outcomes. This paper introduces Evidence-Based Gait Analysis Interpretation Tools (EB-GAIT), a novel framework l...

Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC.

NPJ biofilms and microbiomes
The role of gut dysbiosis in shaping immunotherapy responses is well-recognized, yet its effect on the therapeutic efficacy of chemotherapy and immunotherapy combinations remains poorly understood. We analyzed gut microbiota in non-small cell lung ca...

Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort.

Arthritis research & therapy
BACKGROUND: The variability in treatment response in people with rheumatoid arthritis (RA) warrants the prediction of patients at high risk of treatment failure. Identification of biomarkers linked to clinical remission in RA is currently a challenge...

Leveraging readily available clinical data with machine learning to predict first-line immunotherapy outcomes in non-small cell lung cancer.

International immunopharmacology
BACKGROUND: Immune checkpoint inhibitors (ICIs) are essential first-line treatments for recurrent or metastatic non-small cell lung cancer (NSCLC). However, predicting their effectiveness and the occurrence of immunotherapy-related adverse events (ir...